Abstract:
This webinar explores how incorporating multiple clinically relevant outcomes into a single Net Treatment Benefit (NTB) assessment can transform rare disease clinical trials. By engaging patient advocates and clinicians early in trial design, this approach enhances patient-centricity and clinical relevance while also reducing sample size, shortening development timelines and trial budgets, and increasing the quality of clinical insights.
Key takeaway:
- Elevate the discussion around clinical trial endpoints by exploring how more patient-focused and holistic approach can enhance the way rare disease clinical trials are run.
- Two main benefits from this innovative approach.
Speakers:
- Dr. Sébastien Coppe – Chief Executive Officer, One2Treat
- Dr. Pascal Piedbois – Chief Medical Officer, One2Treat
One2Treat is a forward-thinking partner for biopharmaceuticals companies dedicated to delivering transformative insights in clinical trial design analysis and market access evaluations to support holistic treatment decisions. One2Treat was founded in July 2023 after 4 years of advanced research and software development incubation within IDDI Group. Driven by a commitment to patient-centricity, One2Treat leverages modern statistical methodologies and advanced software solutions ushering in a new era of personalized healthcare.
International Drug Development Institute (IDDI) is THE center of excellence in biostatistics and clinical data science with deep expertise in handling complex data challenges. We offer regulatory statistics, clinical trial design, RTSM, clinical data management, and biostatistical services for pharmaceutical, biotech, and medical device/diagnostic companies.